ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy

Clin Adv Hematol Oncol. 2003 Mar;1(3):162-6.


Excision repair cross-complementation group 1 (ERCC1) is a highly conserved protein and an essential member of the nucleotide excision repair pathway. DNA repair is an important mechanism for resistance to platinum-based chemotherapy. Previous studies have shown that ERCC1 gene expression is associated with clinical outcome to platinum chemotherapy in a variety of cancers. Recently, 2 common polymorphisms in the ERCC1 gene have been described. The first is a single nucleotide polymorphism at codon 188 of the ERCC1 gene that causes a C-->T change but codes for the same amino acid, asparagine. This polymorphism may be associated with differential ERCC1 gene expression. The second is also a signal nucleotide polymorphism in the 3'-untranslated region and may affect MRNA stability. We hypothesized that these 2 polymorphisms may be associated with clinical outcome to platinum-based chemotherapy. We assessed the relationship between these ERCC1 gene polymorphism and clinical outcome to platinum-based chemotherapy in 106 patients with advanced refractory colorectal cancer. We found a significant associated between the ERCC1 codon 118 polymorphism and clinical outcome. Patients with the C/C genotype had a median survival of 15.3 months (95% CI, 6.0-12.1) and 11.1 months (95% CI, 5.8-16.2) for those with C/T and T/T genotypes, respectively. The ERCC1 codon 118 polymorphism may be a useful predictor of clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Colorectal Neoplasms / diagnosis
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / genetics*
  • Colorectal Neoplasms / mortality
  • DNA-Binding Proteins / genetics*
  • Endonucleases / genetics*
  • Female
  • Fluorouracil / therapeutic use
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Organoplatinum Compounds / therapeutic use*
  • Oxaliplatin
  • Polymorphism, Single Nucleotide*
  • Predictive Value of Tests
  • Prognosis
  • Retrospective Studies
  • Survival Analysis


  • DNA-Binding Proteins
  • Organoplatinum Compounds
  • Oxaliplatin
  • ERCC1 protein, human
  • Endonucleases
  • Fluorouracil